STOCK TITAN
  1. Home
  2. SEC-Filings
  3. BGLC

Bionexus Gene La SEC Filings

BGLC NASDAQ

Welcome to our dedicated page for Bionexus Gene La SEC filings (Ticker: BGLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking how BioNexus Gene Lab Corp (BGLC) juggles regional chemical sales and RNA-based diagnostics can feel like reading two companies at once. Annual reports exceed 200 pages, and critical details—such as liquid biopsy trial milestones or composite material margin shifts—are scattered across exhibits. That’s why investors searching for "BioNexus Gene Lab insider trading Form 4 transactions" or "BioNexus Gene Lab quarterly earnings report 10-Q filing" land here first.

Stock Titan’s AI decodes every disclosure the moment it hits EDGAR. Our platform delivers real-time alerts for "BioNexus Gene Lab Form 4 insider transactions real-time," pinpoints R&D outlays in the 10-K, and summarises cash-flow swings in each 10-Q. Prefer plain language? Select "BioNexus Gene Lab SEC filings explained simply" and get concise briefs that clarify how 8-K material events—from new diagnostic approvals to supply-chain agreements—affect revenue. You’ll also find:

  • Side-by-side analysis of chemical vs. healthcare segment revenue in the "BioNexus Gene Lab annual report 10-K simplified" view
  • Instant email or Slack alerts on "BioNexus Gene Lab executive stock transactions Form 4" before markets open
  • AI-highlighted sections of the proxy statement covering "BioNexus Gene Lab proxy statement executive compensation" and board independence

Whether you’re modelling earnings, assessing insider conviction, or simply "understanding BioNexus Gene Lab SEC documents with AI," our coverage is complete. Every 8-K, 10-Q, 10-K, S-1, or Form 4 is indexed, summarised, and linked to source PDFs so you can move from headline to footnote in a click. The result: "BioNexus Gene Lab earnings report filing analysis" delivered in minutes—not hours—letting you act on information instead of searching for it.

Filing

[8-K] BioNexus Gene Lab Corp Common stock Reports Material Event

Rhea-AI Summary
BioNexus Gene Lab Corp (NASDAQ: BGLC) announced the appointment of Ms. Chong Set Fui (Angeline) as Chief Financial Officer and Principal Financial Officer, effective June 17, 2025. Ms. Chong, 62, brings over 25 years of senior financial leadership experience, including her previous role as CFO of Avillion Berhad (2013-2024). She holds ACCA and MIA certifications. The appointment includes dual responsibilities as CFO of MRNA Scientific Sdn. Bhd., a wholly-owned subsidiary. Her compensation package consists of RM15,000 monthly (approx. USD $3,500) plus benefits. Mr. Su-Leng Tan Lee steps down from his interim CFO position. The appointment was vetted by the Nomination and Corporate Governance Committee and Compensation Committee, with an indemnification agreement governed by Wyoming law. BGLC is an emerging growth company listed on Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Bionexus Gene La (BGLC)?

The current stock price of Bionexus Gene La (BGLC) is $3.07 as of June 30, 2025.

What is the market cap of Bionexus Gene La (BGLC)?

The market cap of Bionexus Gene La (BGLC) is approximately 4.9M.

What are the core business segments of BioNexus Gene Lab Corp?

BioNexus Gene Lab Corp operates in both the chemical raw materials supply for various industrial sectors in Southeast Asia and the development of advanced RNA-based genomic diagnostics for early disease detection.

How does the company support early diagnostic services?

The company leverages non-invasive liquid biopsy tests that analyze RNA changes to detect biomarkers linked to multiple diseases, thereby facilitating early and accurate diagnostics.

Which industries benefit from BGLC's chemical raw materials?

Industries such as industrial manufacturing, automotive, aerospace, mechanical, electronic, and appliance production benefit from their high-quality chemical raw materials.

What role do digital health and AI technologies play at BGLC?

BGLC integrates digital health and AI-driven solutions through strategic partnerships and investments, enhancing its genomic diagnostic capabilities and operational efficiencies.

How does the company diversify its portfolio?

Beyond chemical supply and diagnostics, BGLC has diversified into composite material production and renewable energy projects, ensuring a broad market presence and multiple revenue streams.

What is the significance of the Ethereum-focused treasury strategy?

The Ethereum treasury strategy reflects the company’s innovative approach to integrating digital assets and blockchain technology into its corporate finance operations, aligning traditional business practices with modern financial technology.

How does BGLC ensure quality and transparency?

The company maintains strict quality standards across all operations and emphasizes transparency in its processes, fostering trust among investors, customers, and industry regulators.

How does BGLC position itself in a competitive market?

BGLC leverages its dual expertise in advanced diagnostics and industrial chemical supply, complemented by strategic investments and partnerships, to meet the evolving demands of both the healthcare and industrial sectors.
Stock BGLC logo
Bionexus Gene La

NASDAQ:BGLC

BGLC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BGLC Stock Data

4.92M
878.34k
51.38%
0.99%
2.04%
Specialty Chemicals
Services-medical Laboratories
Link
Malaysia
KUALA LUMPUR